BIRMINGHAM, Ala., April 2, 2024 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) will hold its annual meeting of stockholders at 11:00 a.m. CDT, on Thursday, May 2, 2024. The meeting will be held at the Company's Home Office located at 9001 Liberty Parkway in Birmingham, Alabama.
Stockholders planning to attend the meeting will be asked to present valid picture identification, such as a driver's license or passport, and proof of stock ownership. Reporters planning to attend are requested to pre-register with Kennedi Spurling by calling 205-970-5912 or emailing This email address is being protected from spambots. You need JavaScript enabled to view it. no later than Friday, April 26, 2024.
For Encompass Health stockholders not able to attend the meeting and other interested parties, a live audio webcast can be accessed at https://investor.encompasshealth.com. Those interested may replay the audio webcast through an archived link on the same website following the meeting.
About Encompass Health
Encompass Health (NYSE: EHC) is the largest owner and operator of rehabilitation hospitals in the United States. With a national footprint that includes 160 hospitals in 37 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery. Encompass Health is ranked as one of Fortune's World's Most Admired Companies and Modern Healthcare's Best Places to Work in Healthcare. For more information, visit encompasshealth.com, or follow us on our newsroom, Twitter, Instagram and Facebook.
Media Contact:
Kennedi Spurling | 205-970-5912
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations Contact:
Mark Miller | 205-970-5860
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$100.23 |
Daily Change: | -1.11 -1.10 |
Daily Volume: | 776,330 |
Market Cap: | US$10.090B |
November 04, 2024 October 28, 2024 August 05, 2024 July 30, 2024 July 08, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB